CINECA IRIS Institutional Research Information System

CASSADER, Maurizio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.738
EU - Europa 11.710
AS - Asia 8.942
SA - Sud America 627
OC - Oceania 181
AF - Africa 141
Continente sconosciuto - Info sul continente non disponibili 25
Totale 38.364
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.917
CN - Cina 5.236
IT - Italia 1.987
IE - Irlanda 1.507
SE - Svezia 1.451
FR - Francia 1.083
DE - Germania 1.007
UA - Ucraina 895
SG - Singapore 831
FI - Finlandia 718
KR - Corea 658
GB - Regno Unito 636
JP - Giappone 613
AT - Austria 476
CA - Canada 437
PL - Polonia 413
DK - Danimarca 375
MX - Messico 338
VN - Vietnam 323
IN - India 307
ES - Italia 280
BR - Brasile 274
RU - Federazione Russa 166
ID - Indonesia 163
AU - Australia 155
TW - Taiwan 149
HK - Hong Kong 146
TR - Turchia 138
BE - Belgio 124
NL - Olanda 107
GR - Grecia 105
PE - Perù 86
CO - Colombia 76
IR - Iran 68
CL - Cile 65
RO - Romania 65
TH - Thailandia 63
EC - Ecuador 56
AR - Argentina 52
PT - Portogallo 51
CH - Svizzera 47
PH - Filippine 43
CZ - Repubblica Ceca 42
EG - Egitto 40
MY - Malesia 37
SI - Slovenia 34
IL - Israele 30
SN - Senegal 29
NO - Norvegia 25
BY - Bielorussia 24
EU - Europa 24
HU - Ungheria 21
SA - Arabia Saudita 21
NZ - Nuova Zelanda 20
PK - Pakistan 15
ZA - Sudafrica 15
GT - Guatemala 14
IQ - Iraq 12
RS - Serbia 12
LU - Lussemburgo 11
VE - Venezuela 11
QA - Qatar 10
AE - Emirati Arabi Uniti 9
BG - Bulgaria 9
TN - Tunisia 9
MU - Mauritius 8
SK - Slovacchia (Repubblica Slovacca) 8
JO - Giordania 7
LV - Lettonia 7
MM - Myanmar 7
MV - Maldive 7
BD - Bangladesh 6
DZ - Algeria 6
GH - Ghana 6
HN - Honduras 6
HR - Croazia 6
KZ - Kazakistan 6
UZ - Uzbekistan 6
AN - Antille olandesi 5
AZ - Azerbaigian 5
CR - Costa Rica 5
CV - Capo Verde 5
KE - Kenya 5
LB - Libano 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
PA - Panama 4
BA - Bosnia-Erzegovina 3
CY - Cipro 3
ET - Etiopia 3
IS - Islanda 3
JM - Giamaica 3
LK - Sri Lanka 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PG - Papua Nuova Guinea 3
SV - El Salvador 3
UY - Uruguay 3
AL - Albania 2
BF - Burkina Faso 2
Totale 38.327
Salva come PNG Salva come JPEG
Città #
Beijing 1.971
Chandler 1.851
Dublin 1.493
Ann Arbor 1.240
Fairfield 828
Houston 784
Jacksonville 692
Ashburn 680
Villeurbanne 630
Wilmington 609
Princeton 579
Singapore 574
Woodbridge 568
Redwood City 484
Medford 467
Vienna 438
Nyköping 437
Dearborn 412
Torino 372
Shanghai 366
Seattle 355
Warsaw 325
Cambridge 297
Pisa 296
Guangzhou 243
Dong Ket 223
Boston 216
Nanjing 216
Hangzhou 187
Boardman 173
Ottawa 160
Tokyo 143
Fremont 125
Milan 121
Jakarta 113
Wuhan 110
Chengdu 99
Taipei 97
Norwalk 95
Pune 90
Rome 86
New York 85
Chongqing 81
Toronto 80
Hefei 74
Helsinki 70
London 68
Shenyang 68
Changsha 64
Jinan 64
Tianjin 64
Turin 64
Brussels 63
Santa Clara 59
San Diego 58
Verona 58
Kunming 57
Munich 56
Lima 53
Phoenix 51
Los Angeles 48
Washington 48
Falls Church 47
Istanbul 46
Menlo Park 46
Zhengzhou 46
Changchun 44
San Mateo 43
Seoul 43
Xian 43
São Paulo 42
Central District 41
Santiago 41
Mexico City 34
Nanchang 34
Central 33
Frankfurt am Main 33
Fuzhou 33
Düsseldorf 32
Madrid 32
Silver Spring 30
West Jordan 30
Athens 29
Bogotá 29
Duncan 29
Mexico 28
Mountain View 28
Saint-hubert 28
Berlin 27
Lachine 27
Chicago 25
Hong Kong 25
Xiamen 25
Paris 24
Saint Petersburg 24
Mumbai 23
Riverton 22
Sydney 22
Barcelona 21
Buenos Aires 20
Totale 21.807
Salva come PNG Salva come JPEG
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.363
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1.525
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 966
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 887
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 814
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 755
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 701
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 660
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 558
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 493
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 426
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 361
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 303
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 286
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 269
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 252
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 230
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 224
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 219
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 211
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 201
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 194
Body fat and C-reactive protein levels in healthy non-obese men. 189
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 189
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 189
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 186
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 186
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 184
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 180
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances 179
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 173
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 172
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 169
The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. 167
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 161
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 160
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 160
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 155
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 154
Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man 153
Body fat is the main predictor of fibrinogen levels in healthy non-obese men 149
Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man 149
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 147
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 147
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 146
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 145
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 145
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 145
Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria 145
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 144
Relationships between human serum resistin, inflammatory markers and insulin resistance 143
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 141
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 140
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 138
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 137
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 137
Lipoprotein(a) and insulin treatment in non insulin dependent diabetic patients 136
Lipoprotein(a) and insulin treatment in NIDDM patients 136
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 136
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 133
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 132
Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. 132
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 130
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 129
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 129
Metabolic handling of an oral fat load in NAFLD patients. 127
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 125
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 124
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 124
Age related changes of glucagon binding and activity in isolated rat hepatocytes. 122
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 122
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 120
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 120
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 120
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 119
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 118
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 116
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 114
Effetto della terapia steroidea sul controllo glicemico nel diabete insulino-trattato: confronto Deflazacort-Prednisone. 113
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 112
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 112
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 111
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 111
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 110
Nel soggetto normale la ferritemia correla con l’HOMA. 110
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 110
Adiponectin gene polymorphism modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH 108
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. 106
Dietary interventions modify the gut microbiota during pregnancy in patients with gestational diabetes mellitus (GDM) 106
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 105
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 104
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up 103
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? 103
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 103
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 102
Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents 102
Plasma Adiponectin Levels in Primary Biliary Cirrhosis: A Novel Perspective for Link Between Hypercholesterolemia and Protection Against Atherosclerosis 100
Phytosterol-Enriched Yogurt Increases LDL Affinity and Reduces CD36 Expression in Polygenic Hypercholesterolemia 100
Totale 23.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.194
article - articoli 0
book - libri 0
conference - conferenze 31.534
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.728
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.034 0 0 0 535 370 871 603 391 489 496 600 679
2020/20214.931 567 327 318 290 437 339 410 233 510 521 391 588
2021/20225.690 246 334 282 408 389 290 466 404 306 515 959 1.091
2022/20236.959 859 481 197 556 570 1.698 654 454 592 220 349 329
2023/20244.560 452 557 307 333 350 551 333 292 79 358 399 549
2024/20251.494 320 583 489 102 0 0 0 0 0 0 0 0
Totale 39.664